How should patients be selected for metastatic-site directed radiotherapy in rhabdomyosarcoma?
Should this be based off of the response? or the site of disease such as bone vs soft tissue?
What data are there to dictate that the prior (response, tissue type) should dictate RT indication (site selection), dose &/or volume?
Dose: 50.4 Gy (ARST 0431) or 40 Gy (ARST 1431)?
Volume: Pre- vs. post-chemo volume?
Timing: At the time of primary site treatment or end of therapy or interdigitated?
Should response guide RT indication or site selection?
1 Answer
Mednet Member
Radiation Oncology · University of North Carolina Chapel Hill School of Medicine
Answered on · Updated on
Definitive therapy to sites of metastases at the time of diagnosis is recommended for all patients with metastatic disease on the most recent COG trials (both ARST1431 including intermediate risk patients and ARST0431 including high risk patients). We typically treat the metastatic sites at the end of chemotherapy for consolidation as is done on ARST1431, although ARST0431 did metastatic site treatment at the same time as primary site treatment, and sometimes there may be a reason to treat earli...
Join for free or sign in to see the full answer